Efficacy of durvalumab consolidation treatment in patients with unresectable locally advanced non-small cell lung cancer: An observational study
Latest Information Update: 19 Jul 2021
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 19 Jul 2021 New trial record